natgillin/translations-raw huggingface dataset:
On the basis of the scientific conclusions for regadenoson the CHMP is of the opinion that the benefit-risk balance of the medicinal product containing regadenoson is favourable subject to the proposed changes to the product information.
Na podlagi znanstvenih zaključkov za regadenozon odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravila, ki vsebuje regadenozon, ugodno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for rivastigmine the CHMP is of the opinion that the benefit-risk balance of the medicinal products containing rivastigmine is favourable subject to the proposed changes to the product information.
Na podlagi znanstvenih zaključkov za rivastigmin odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil, ki vsebujejo rivastigmin, ugodno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for sevelamer the CHMP is of the opinion that the benefit- risk balance of the medicinal product(s) containing sevelamer is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za sevelamer odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) sevelamer nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for sevelamer the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing sevelamer is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za sevelamer odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) sevelamer nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for Siklos, the CHMP is of the opinion that the benefit- risk balance of the medicinal product containing the active substance HYDROXYCARBAMIDE is favourable subject to the proposed changes to the product information.
Na podlagi znanstvenih zaključkov za zdravilo Siklos je CHMP mnenja, da je razmerje med koristmi in tveganji za zdravilo, ki vsebuje zdravilno učinkovino HIDROKSIKARBAMID, ugodno ob upoštevanju predlaganih sprememb informacij o zdravilu.
On the basis of the scientific conclusions for sofosbuvir the CHMP is of the opinion that the benefit- risk balance of the medicinal product(s) containing sofosbuvir is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za sofosbuvir odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) sofosbuvir nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for tadalafil the CHMP is of the opinion that the benefit- risk balance of the medicinal product(s) containing tadalafil is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za tadalafil odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) tadalafil nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for temozolomide the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing temozolomide is favourable subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za temozolomid odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) zdravilno učinkovino temozolomid, ugodno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for TERIFLUNOMIDE the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing TERIFLUNOMIDE is favourable subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za TERIFLUNOMID odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravila, ki vsebuje TERIFLUNOMID, ugodno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for thalidomide the CHMP is of the opinion that the benefit-risk balance of the medicinal product containing thalidomide is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za talidomid odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravila, ki vsebuje talidomid, nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for trametinib the CHMP is of the opinion that the benefit- risk balance of the medicinal product(s) containing trametinib is unchanged subject to the proposed changes to the product information.
Na podlagi znanstvenih zaključkov za trametinib odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) trametinib, ugodno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for umeclidinium bromide / vilanterol the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing umeclidinium bromide / vilanterol is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za umeklidinijev bromid/vilanterol odbor CHMP meni, da je razmerje koristi in tveganj za zdravilo/zdravila, ki vsebuje(jo) umeklidinijev bromid/vilanterol, nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for Vipidia, the CHMP is of the opinion that the benefit- risk balance of the medicinal product containing the active substance alogliptin is favourable subject to the proposed changes to the product information.
Na podlagi znanstvenih zaključkov za zdravilo Vipidia odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravila, ki vsebuje zdravilno učinkovino alogliptin, ugodno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for Vipidomet, the CHMP is of the opinion that the benefit- risk balance of the medicinal product containing the active substance alogliptin/ metformin is favourable subject to the proposed changes to the product information.
Na podlagi znanstvenih zaključkov za zdravilo Vipdomet odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravila, ki vsebuje zdravilni učinkovini alogliptin in metformin, ugodno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for vismodegib, the CHMP is of the opinion that the benefit- risk balance of the medicinal product containing vismodegib is unchanged subject to the proposed changes to the product information.
Na podlagi znanstvenih zaključkov za vismodegib odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravila, ki vsebuje vismodegib, nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for zaleplon the CHMP is of the opinion that the benefit-risk balance of the medicinal product containing zaleplon is favourable subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za zaleplon odbor CHMP meni, da je je razmerje med koristjo in tveganjem zdravila, ki vsebuje zdravilno učinkovino zaleplon, ugodno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of the scientific conclusions for zoledronic acid (indicated for cancer and fractures) the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing zoledronic acid (indicated for cancer and fractures) is unchanged subject to the proposed changes to the product information.
Na podlagi znanstvenih zaključkov za zoledronsko kislino (indicirano pri rakavih obolenjih in zlomih) odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) zoledronsko kislino (indicirano pri rakavih obolenjih in zlomih) nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
On the basis of these immunogenicity data, the efficacy of Cervarix is inferred from 9 to 14 years of age.
Na osnovi teh podatkov o imunogenosti, lahko sklepamo o učinkovitosti cepiva Cervarix pri osebah, starih od 9 do 14 let.
On the basis of this immunogenicity bridging, the efficacy of a 2-dose regimen of Gardasil 9 in 9 to 14-year-old girls and boys is inferred.
Na osnovi primerjave imunogenosti lahko sklepamo o učinkovitosti 2-odmerne sheme cepljenja s cepivom Gardasil 9 pri deklicah in dečkih, starih od 9 do 14 let.
On the basis of this immunogenicity bridging, the efficacy of Gardasil 9 in 9- through 15-year-old girls and boys is inferred.
Na osnovi primerjave imunogenosti lahko sklepamo o učinkovitosti cepiva Gardasil 9 pri deklicah in dečkih, starih od 9 do 15 let.
On the basis of this immunogenicity bridging, the efficacy of Silgard in 9- to 15-year-old boys is inferred.
Na podlagi te primerjave imunogenosti sklepajo, da je cepivo Silgard učinkovito pri dečkih, starih od 9 do 15 let.
On the basis of this immunogenicity bridging, the efficacy of Silgard in 9- to 15-year-old girls is inferred.
Na osnovi imunogenosti se lahko sklepa o učinkovitosti cepiva Silgard pri 9- do 15-letnih deklicah.
On the basis of this information, the PRAC agreed on the need to list this adverse reaction in the product information.
Na podlagi teh informacij je odbor PRAC soglašal, da je treba ta neželeni učinek navesti v informacijah o zdravilu.
On the day of applying Bravecto spot-on solution treated animals should not be allowed to sleep in the same bed as their owner, especially children.
Na dan nanosa zdravila Bravecto v obliki raztopine za kožni nanos zdravljene živali ne smejo spati v isti postelji z lastniki, zlasti ne z otroki.
On the day of first treatment this veterinary medicinal product results in adequate flea adulticidal activity within 12 hours after application.
Na dan prvega nanosa ima zdravilo za uporabo v veterinarski medicini zadosten adulticiden učinek na bolhe v 12 urah po nanosu.
On the day of PCI, prior to catheterization, 53.2 % received a thienopyridine (clopidogrel 52.7 %; ticlopidine 0.5 %) – mostly as a loading dose (300 mg or more).
Na dan perkutanega koronarnega posega je pred katetrizacijo 53,2 % bolnikov prejelo tienopiridin (klopidogrel 52,7 % in tiklopidin 0,5 %), večinoma v obliki udarnega odmerka (300 mg ali več).
On the day of surgery, most subjects received a second injection.
Na dan kirurškega posega je večina oseb prejela še drugo injekcijo.
On the day of treatment, treated animals should not be permitted to sleep in the same bed as their owner, especially children.
Na dan zdravljenja zdravljene živali ne smejo ležati v isti postelji kot lastnik živali, še posebno ne otroci.
On the day of treatment, treated animals should not be permitted to sleep in the same bed as their owner, especially children.
Na dan zdravljenja zdravljene živali ne smejo ležati v isti postelji z lastnikom živali, še posebno ne z otroki.
On the day of treatment, treated animals should not be permitted to sleep in the same bed as their owner, especially children.
Na dan zdravljenja zdravljene živali ne smejo ležati v isti postelji z lastnikomi živali, še posebno ne otroci.
On the day of treatment, treated dogs should not be permitted to sleep with their owners, especially children.
Na dan nanosa, naj psi ne spijo pri lastnikih, še posebno ne pri otrocih.
On the day of, or the day following administration of spinosad at a dose of 45–70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively.
Na dan dajanja spinosada v odmerku 45–70 mg/kg telesne mase ali naslednji dan so v terenski študiji opazili 5,6 % pojavnost bruhanja po zdravljenju prvi mesec, 4,2 % po zdravljenju drugi mesec in 3,6 % po zdravljenju tretji mesec.
On the day of, or the day following administration of spinosad at a dose of 50–75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment.
Na dan dajanja spinosada v odmerku 50–75 mg/kg telesne mase ali naslednji dan so v terenski študiji opazili pojavnost bruhanja med 6 % in 11 % v prvih treh mesecih zdravljenja.
On the first day of treatment take 200 mg (one 5 ml spoonful) once.
Prvi dan zdravljenja zaužijte enkrat 200 mg (eno 5 ml žličko).
On the first day of treatment take 200 mg (one 5 mL spoonful) once.
Prvi dan zdravljenja zaužijte enkrat 200 mg (eno polno 5 ml žličko).
On the first day of treatment the patient starts with Leganto 2 mg/24 h.
Prvi dan zdravljenja bolnik začne z obližem zdravila Leganto 2 mg/24 h.
On the first day of treatment the patient starts with Neupro 2 mg/24 h.
Prvi dan zdravljenja bolnik začne z obližem zdravila Neupro 2 mg/24 h.
On the first day of treatment, inspiratory capacity under exercise was significantly improved (250 ml, p<0.001) compared to placebo.
Prvi dan zdravljenja se je inspiratorna kapaciteta med naporom statistično značilno povečala v primerjavi z uporabo placeba (za 250 ml, p<0,001).
On the first day of treatment, start with Leganto 2 mg (package marked “Week 1)“, and use one Leganto 2 mg transdermal patch daily.
Prvi dan zdravljenja začnite z zdravilom Leganto 2 mg (pakiranje označeno z nalepko “1. teden“) in uporabite po en transdermalni obliž zdravila Leganto 2 mg na dan.
On the first day of treatment, start with Neupro 2 mg (package marked “Week 1)“, and use one Neupro 2 mg transdermal patch daily.
Prvi dan zdravljenja začnite z zdravilom Neupro 2 mg (pakiranje označeno z nalepko “1. teden“) in uporabite po en transdermalni obliž zdravila Neupro 2 mg na dan.
On the first visit, the surgeon will evaluate your cartilage defect during an exploratory operation (arthroscopy).
Ob prvem obisku bo kirurg med eksplorativno operacijo (artroskopijo) ocenil vašo okvaro hrustanca.
On the first “Patch Change Day”, Day 8, take off the used patch
Prvi dan zamenjave obliža, torej na 8. dan, uporabljeni obliž odstranite.
On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.
Četrti dan po zadnjem odmerku varfarina so vsi izvidi (vključno s PČ, aPTČ, zaviranjem aktivnosti faktorja Xa in ETP (Endogenous Thrombin Potential)) kazali samo še učinke rivaroksabana.
On the front of the ampoule tail
Na sprednji strani spodnjega dela ampule
On the front of your thighs or
na sprednji strani stegen ali
On the inner part of the carton:
Na notranjem delu kartonske škatle:
on the need to continue on a low-fat diet and avoid drinking alcohol
potrebe po nadaljevanju diete z majhnim vnosom maščob in potrebo po izogibanju alkoholu;
On the other hand effective anti-epileptic therapy must not be interrupted since the worsening of the disease is harmful to both the mother and the unborn child.
Po drugi strani pa učinkovitega zdravljenja z antiepileptiki ne smemo prekiniti, saj je poslabšanje bolezni škodljivo za mater in nerojenega otroka.
On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease ≥ 20% (13.1 % versus 6.1%), absolute LVEF decrease ≥ 30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5 %); pogostejši so bili tudi hudi kardiotoksični učinki: kongestivno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje LVEF ≥ 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje LVEF ≥ 30 % (6,2 % v prim. z 1,1 %).
On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease ≥ 20% (13.1 % versus 6.1%), absolute LVEF decrease ≥ 30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5 %); pogostejši so bili tudi hudi kardiotoksični učinki: zastojno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje iztisnega deleža levega prekata ≥ 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje iztisnega deleža levega prekata ≥ 30 % (6,2 % v prim. z 1,1 %).
On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease ≥ 20% (13.1% versus 6.1%), absolute LVEF decrease ≥ 30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5 %); pogostejši so bili tudi hudi kardiotoksični učinki: kongestivno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje LVEF ≥ 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje LVEF ≥ 30 % (6,2 % v prim. z 1,1 %).
On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease ≥ 20% (13.1% versus 6.1%), absolute LVEF decrease ≥ 30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5%); pogostejši so bili tudi hudi kardiotoksični učinki: kongestivno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje LVEF ≥ 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje LVEF ≥ 30 % (6,2 % v prim. z 1,1 %).
On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease  20% (13.1% versus 6.1%), absolute LVEF decrease  30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5 %); pogostejši so bili tudi hudi kardiotoksični učinki: kongestivno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje LVEF ≥ 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje LVEF ≥ 30 % (6,2 % v prim. z 1,1 %).
On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease  20% (13.1% versus 6.1%), absolute LVEF decrease  30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5%); pogostejši so bili tudi hudi kardiotoksični učinki: kongestivno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje LVEF ≥ 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje LVEF ≥ 30 % (6,2 % v prim. z 1,1 %).
On the other hand, AC arm showed a higher incidence of severe anemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease ≥ 20% (13.1 % versus 6.1%), absolute LVEF decrease ≥ 30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5 %); pogostejši so bili tudi hudi kardiotoksični učinki: kongestivno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje LVEF > 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje LVEF > 30 % (6,2 % v prim. z 1,1 %).
On the other hand, AC arm showed a higher incidence of severe anemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease  20% (13.1% versus 6.1%), absolute LVEF decrease  30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5 %); pogostejši so bili tudi hudi kardiotoksični učinki: kongestivno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje LVEF ≥ 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje LVEF ≥ 30 % (6,2 % v prim. z 1,1 %).
On the other hand, AC arm showed a higher incidence of severe anemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease  20% (13.1% versus 6.1%), absolute LVEF decrease  30% (6.2% versus 1.1%).
Po drugi strani je bila huda anemija pogostejša v kraku AC kot v kraku AT (15,8 % v prim. z 8,5%); pogostejši so bili tudi hudi kardiotoksični učinki: kongestivno srčno popuščanje (3,8 % v prim. z 2,8 %), absolutno zmanjšanje LVEF ≥ 20 % (13,1 % v prim. s 6,1 %), absolutno zmanjšanje LVEF ≥ 30 % (6,2 % v prim. z 1,1 %).
On the patch-change day, remove the used patch and immediately stick the new patch on to a different area of skin of your abdomen.
Na dan, ko menjavate obliž, odstranite uporabljeni obliž in takoj nalepite novega na drugo mesto na koži trebuha.
On the primary efficacy endpoint, Weekly Rate of Cataplexy episodes (WRC), the results with pitolisant were significantly superior to those in the placebo group (p < 0.0001), with a progressive 64% decrease from baseline to end of treatment (Figure 2).
Pri primarnem opazovanem dogodku za oceno učinkovitosti, tedenski stopnji epizod katapleksije (Weekly Rate of Cataplexy – WRC), so bili rezultati v skupini s pitolizantom znatno boljši kot v skupini s placebom (p < 0,0001), pri čemer so zabeležili progresivno 64-odstotno znižanje od izhodišča do konca zdravljenja (slika 2).
On the second day after administration of a 6 mg/kg dose to HD and CAPD patients the daptomcyin AUC was approximately 1.3-fold higher than that observed after a second 6 mg/kg dose in patients with normal renal function.
V drugem dnevu po aplikaciji odmerka 6 mg/kg bolnikom na hemodializi ali kontinuirani ambulantni peritonealni dializi (CAPD) je bila njihova AUC daptomicina približno 1,3-krat večja kot pri bolnikih z normalno ledvično funkcijo po drugem odmerku 6 mg/kg.
On the second visit the surgeon will:
Ob drugem obisku vam bo kirurg:
On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal.
Na tej podlagi prispeva M-IV k učinkovitosti približno trikrat toliko kot pioglitazon, relativna učinkovitost M-II pa je minimalna.
On this basis, the efficacy of contraceptive pills metabolised by CYP3A4 used concomitantly with vemurafenib might be decreased.
Tako je lahko učinkovitost kontracepcijskih tablet, ki se presnavljajo s CYP3A4 in se uporabljajo sočasno z vemurafenibom, zmanjšana.
ON time increase ≥60 minutes
gibanjem ≥ 60 minut
ON time without troublesome dyskinesia (hrs) (c)
Obdobje »vklopa« brez moteče diskinezije (ure) (c)
ON TOBI Podhaler
jemanje zdravila TOBI Podhaler
On treatment, some dogs will be free of seizures, in other dogs a reduction of the number of seizures will be observed, whilst others will be non-responders.
Med zdravljenjem nekateri psi epileptičnih napadov ne bodo imeli, pri drugih jih bo manj, nekateri pa se ne bodo odzvali.
On two occasions prior to initiation of treatment
ob dveh priložnostih pred uvedbo zdravljenja,
On urinalysis, the percentage of patients with protein values of 1+ or greater was similar for Tecfidera (43%) and placebo-treated patients (40%).
Analiza urina je pokazala podoben odstotek bolnikov z vrednostmi beljakovin 1+ ali višjimi za zdravilo Tecfidera (43 %) in bolnike, ki so prejemali placebo(40 %).
On very rare occasions the following have been reported:
V zelo redkih primerih poročajo o naslednjih neželenih učinkih:
On very rare occasions transient focal irritation may also be observed.
V manjši meri so v teh primerih opazili tudi prehodno vzdraženje kože.
On- treatment virologic failure
Virološki neuspeh med zdravljenj-em
On-site instructions on the use of the fluorescence-microscope, including pitfalls and recognition of problems;
navodilih za uporabo fluorescenčnega mikroskopa, vključno s pastmi in prepoznavanjem težav, ki bodo podana na mestu tečaja;
On-therapy genotypes
Zdravljeni genotipi